CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
New Era for Renal-Protective Therapy in Type 2 Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors
Chan-Hee Jung
Endocrinol Metab. 2021;36(2):339-341.   Published online April 27, 2021
DOI: https://doi.org/10.3803/EnM.2021.203

Excel Download

New Era for Renal-Protective Therapy in Type 2 Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors
Endocrinology and Metabolism. 2021;36(2):339-341   Crossref logo
Link1 Link2 Link3

The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
Cardiovascular Diabetology. 2020;19(1):   Crossref logo
Link1 Link2 Link3

The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
. 2020;   Crossref logo
Link1 Link2

The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
. 2020;   Crossref logo
Link1 Link2

Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Endocrinology and Metabolism. 2021;36(2):388-400   Crossref logo
Link1 Link2 Link3

Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale
Drug Design, Development and Therapy. 2017;Volume11:923-937   Crossref logo
Link1 Link2

The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Diabetes/Metabolism Research and Reviews. 2014;30(4):269-283   Crossref logo
Link1 Link2

Health expenditure and health services utilization comparison of patients with type 2 diabetes on sodium–glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: evidence from 2015 to 2016 medical expenditure panel survey
Journal of Pharmaceutical Health Services Research. 2020;11(4):395-401   Crossref logo
Link1 Link2 Link3 Link4 Link5

Healthcare resource utilization after initiation of sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors or other glucose‐lowering drugs in Japanese patients with type 2 diabetes
Diabetes, Obesity and Metabolism. 2021;23(S2):28-39   Crossref logo
Link1 Link2 Link3

Renal outcomes with dipeptidyl peptidase-4 inhibitors
Diabetes & Metabolism. 2018;44(2):101-111   Crossref logo
Link1 Link2